Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand

Emerging Infectious Diseases

Volumn 13, Issue 7, 2007, Pages 1001-1007

  Akksilp, Somsak ^a   Karnkawinpong, Opart ^a   Wattanaamornkiat, Wanpen ^a   Viriyakitja, Daranee ^a   Monkongdee, Patama ^a   Sitti, Walya ^a   Rienthong, Dhanida ^a   Siraprapasiri, Taweesap ^a   Wells, Charles D ^b   Tappero, Jordan W ^a,b   Varma, Jay K ^a,b,c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CDC/HIV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA COLLECTION METHOD; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PROSPECTIVE STUDY; REDUCTION; RISK FACTOR; SCHOOL CHILD; SMEAR; THAILAND; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34447269980     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1307.061506     Document Type: Article

References (28)

1. World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: The Organization; 2004. WHO/HTM/TB/2004.330. [cited 30 Apr 2007]. Available from http://whqlibdoc.who.int/hq/2004/who_htm_tb_2004.330.pdf
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. Geneva: The Organization; 2005. WHO/HTM/TB/2005.349.
3. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143-52.
4. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis. 1987;136:570-4.
5. Ackah AN, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly IM, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet. 1995;345:607-10.
6. Nunn P, Brindle R, Carpenter L. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Am Rev Respir Dis. 1992;146:849-54.
7. Elliott AM, Halwiindi B, Hayes RJ. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg. 1995;89:78-82.
8. Freudenb erg N, Fahs M, Galea S, Greenberg A. The impact of New York City's 1975 fiscal crisis on tuberculosis, HIV, and homicide syndemic. Am J Public Health. 2006;96:424-34.
9. Joint United Nations Programme on HIV/AIDS. 2006 Report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2006. [cited 30 Apr 2007]. Available from http://www.unaids.org/en/HIV_data/ 2006GlobalReport/default.asp
10. World Health Organization. Proceedings of the WHO HIV/TB conference for the Mekong Sub-region, Ho Chi Minh City, Viet Nam, October 10-14, 2005. [cited 30 Apr 2007]. Available from http://www.un.org.vn/who/docs/mekonghivtb/ proceedings.pdf
11. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the Euro-SIDA study: an observational study. Lancet. 2003;362:22-9.
12. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al., and the HIV outpatient study investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-60.
13. World Health Organization. TB/HIV: a clinical manual, second edition. 2004. Geneva: The Organization; 2004. [cited 30 Apr 2007]. Available from http://whqlibdoc.who.int/publications/2004/9241546344.pdf
14. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active anti-retroviral therapy. J Infect Dis. 2004;190:1670-6.
15. Dean GL, Edwards SG, Ives NJ, Mathews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83.
16. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med. 2006;173:350-6.
17. Breen RA, Miller RF, Gorsuch T, Smith CJ, Ainsworth J, Ballinger J, et al. Virological response to highly active anti-retroviral therapy is unaffected by anti-tuberculosis therapy. J Infect Dis. 2006;193:1437-40.
18. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:42-6.
19. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: The Organization; 2003. [cited 30 Apr 2007].Available from http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng. pdf
20. Yu LM, Easterbrook PJ, Marshall T. Relationship between CD4 count and CD4% in HIV-infected people. Int J Epidemiol. 1997;26:1367-73.
21. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148:1292-7.
22. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active anti-retroviral therapy. Clin Infect Dis. 2000;30:S5-14.
23. Martin DJ, Sim JG, Sole GJ, Rymer L, Shalekoff S, van Niekerk AB, et al. CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:386-91.
24. Teck R, Ascurra O, Gomani P, Manzi M, Pasulani O, Kusamale J, et al. WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for anti-retroviral treatment: relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis. 2005;9:258-62.
25. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, et al. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003;187:1967-71.
26. Abouya L, Coulibaly IM, Wiktor SZ, Coulibaly D, N'kragbo M, N'gbo A, et al. The Côte d'Ivoire national HIV counseling and testing program for tuberculosis patients: implementation and analysis of epidemiologic data. AIDS. 1998;12:505-12.
27. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-75.
28. Tansuphasawadikul S, Amornkul PN, Tanchanpong C, Limpakarnjanarat K, Kaewkungwal J, Likanonsakul S, et al. Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999;21:326-32.